AZA Plus LEN or VOR Do Not Improve Response Rates in MDS or CMML, Though DFS and OS Still an Open Question

Article Information

DOI 
http://dx.doi.org/10.1177/1559897714568624
Published By 
SAGE Publications
Print ISSN 
1559-8977
Online ISSN 
2155-756X
Copyright & Usage 
© 2014 SAGE Publications

Author Information

  1. Lynne Lederman
  1. Mikkael Sekeres, MD
    1. Cleveland Clinic, Cleveland, Ohio, USA
View Full Text

Article usage

AbstractFullPDF
Apr 2015600
May 2015200
Jun 2015900
Jul 2015011
Aug 20152510
Sep 20155500
Oct 2015232
Nov 20158200
Total18153

Note: Article usage statistics are calculated and reported monthly.

Cited By...

  • No citing articles found.
Back to top

Tools

View Full Page PDF
Citation Tools
Email
AZA Plus LEN or VOR Do Not Improve Response Rates in MDS or CMML, Though DFS and OS Still an Open Question
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

myelodysplastic syndrome
chronic myelomonocytic leukemia
prognosis
combination treatment
azacitidine
lenalidomide
vorinostat
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia